SARS-CoV-2 Seroprevalence in Kenya dataset – User Guide

Persistent identifier

10.17037/DATA.00003755

Description

A quantitative data containing information on COVID seroprevalence in pregnant women, based upon an analysis of 2,495 samples collected from 1,811 women between March 2020 – March 2022 in Kilifi County, Kenya. This is a sub-set of women in the PRECISE Study where pregnant women were recruited to the study and followed up during their pregnancy.

Data collection methods

This is an ancillary study of the PRECISE study (Pregnancy Care Integrating Translational Science, Everywhere), in which a pregnancy cohort was recruited in The Gambia, Kenya, and Mozambique, with the collection of extensive sociological and clinical data and biological samples throughout woman's pregnancy, until 6 weeks post-delivery. Samples and data from the PRECISE study were used for this work.

Data access statement

To access the data, requests must be made to the P.I. in Kenya. The request will be reviewed by both the Gambian Team and the PRECISE Consortium Data and Sample Access Committee, which consists of the leads of all the collaborating units as well as a panel of experts. The committee will review the request based on scientific value and to ensure there is no overlap with existing work. If the study is approved, before data is shared, Data User Responsibilities Agreements must be signed.

Geographic regions

Data collected in Kilifi County, Kenya.

Key dates

Data capture was ongoing from July 2019 – December 2022 as part of PRECISE study, a subset of these samples were used for the seroprevalence analysis, these included samples collected between March 2020 – March 2022.  The laboratory analysis took place from 23^rd May 2022 – 22^nd September.

Quality controls

The three SARS-CoV-2 ELISA assays were determined to be 100% sensitive and 100% specific using 20 known negative samples collected prior to the COVID-19 pandemic and 22 positive samples (confirmed PCR positive clinical cases with spike and nucleocapsid antibodies). In addition, we conducted a SARS-CoV-2 serologic assessment using randomly selected serum aliquots from the PRECISE cohort from the pre-pandemic period (July to December 2019, maximum 20 samples per month, total 113) using the Wantai anti-SARS-CoV-2 ELISA to assess its specificity. These samples were processed and stored with the same procedures. All 113 samples were negative for SARS-CoV-2 total antibody.

Population

Pregnant women living in Kilifi Country.

Privacy

Participant identifiers have been removed from the dataset.

Ethics

Keywords

SARS-CoV-2, COVID-19, Seroprevalence, Pregnancy, Kenya

Language of written material

English

Additional information

The PRECISE Network is a consortium led by King’s College London in collaboration with three Clinical Network Hubs (LSHTM at MRC The Gambia, the Aga Khan University, Kenya, and Centro de Investigação em Saúde de Manhiça, Mozambique) and five partnering institutes (Midland State University, Zimbabwe; London School of Hygiene and Tropical Medicine, UK; St Georges University London, UK; University of Oxford, UK; University of British Columbia, Canada). The consortium is governed by the Project Executive Group which is the projects decision making forum. PRECISE Project Executive Group (PEG) consists of the PRECISE Principal Investigator, and the three Clinical Hub Principal Investigators, the Working Group Chairs and the PRECISE management team.

The PRECISE Data and Sample Committee are responsible for the use of data and samples within the network. The PRECISE Data and Access Committee consists of the PRECISE Principal Investigator, and the three Clinical Hub Principal Investigators. In addition, there are 14 additional experts on the panel whose input is requested depending on the data requests that we receive. These include statisticians, epidemiologists, and experts in health geography, child development, maternal health, preterm birth and molecular biology/pathology.

Project information

Creators

File description